Clinical Trial Update: A Safety and Efficacy Study of Sufentanil Transdermal System in Patients With Chronic Pain Due to Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating the sufentanil transdermal system for cancer-related chronic pain has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Pain

Drugs mentioned

• Sufentanil Transdermal System (sufentanil)

Snippet

Sponsor: Labtec GmbH | Conditions: Chronic Pain | Phase 2 | Status: WITHDRAWN